AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
dalbavancin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| vancomycin related compounds | 777 | 171500-79-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Dalbavancin, a semisynthetic lipoglycopeptide, interferes with cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the stem pentapeptide in nascent cell wall peptidoglycan, thus preventing cross-linking. Dalbavancin is bactericidal in vitro against Staphylococcus aureus and Streptococcus pyogenes at concentrations similar to those sustained throughout treatment in humans treated according to the recommended dosage regimen.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1.50 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 0.14 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 0.01 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.02 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 170 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 18, 2014 | EMA | ||
| May 23, 2014 | FDA | DURATA THERAPS INTL |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Back pain | 45.98 | 45.18 | 35 | 1133 | 370961 | 110217170 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01XA04 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER ANTIBACTERIALS Glycopeptide antibacterials |
| FDA CS | M000640741 | Lipoglycopeptides |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| FDA EPC | N0000191281 | Lipoglycopeptide Antibacterial |
| CHEBI has role | CHEBI:33281 | antimicrobial agent |
| CHEBI has role | CHEBI:36047 | antibacterial drug |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
Related Drugs by ATC class:
J01XA Glycopeptide antibacterials 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
| Bacterial infection of skin | indication | 128936008 | |
| Staphylococcal infection of skin | indication | 402938009 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.53 | acidic |
| pKa2 | 7.41 | acidic |
| pKa3 | 8.05 | acidic |
| pKa4 | 8.37 | acidic |
| pKa5 | 8.65 | acidic |
| pKa6 | 9.93 | acidic |
| pKa7 | 11.23 | acidic |
| pKa8 | 11.94 | acidic |
| pKa9 | 11.99 | acidic |
| pKa10 | 12.61 | acidic |
| pKa11 | 12.91 | acidic |
| pKa12 | 13.23 | acidic |
| pKa13 | 13.59 | acidic |
| pKa14 | 13.73 | acidic |
| pKa15 | 9.21 | Basic |
| pKa16 | 6.62 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 500MG BASE/VIAL | DALVANCE | ABBVIE | N021883 | May 23, 2014 | RX | POWDER | INTRAVENOUS | 6900175 | May 23, 2028 | TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) IN ADULT AND PEDIATRIC PATIENTS USING A TWO-DOSE REGIMEN OF DALBAVANCIN |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D03640 | KEGG_DRUG |
| 1539239 | RXNORM |
| C1172636 | UMLSCUI |
| CHEBI:82721 | CHEBI |
| CHEMBL3301669 | ChEMBL_ID |
| CHEMBL3301650 | ChEMBL_ID |
| DB06219 | DRUGBANK_ID |
| C469289 | MESH_SUPPLEMENTAL_RECORD_UI |
| 10876 | IUPHAR_LIGAND_ID |
| 7978 | INN_ID |
| 808UI9MS5K | UNII |
| 16134627 | PUBCHEM_CID |
| 221316 | MMSL |
| 30328 | MMSL |
| 399068 | MMSL |
| d08264 | MMSL |
| 015537 | NDDF |
| 015541 | NDDF |
| 703917001 | SNOMEDCT_US |
| 703918006 | SNOMEDCT_US |
| 703919003 | SNOMEDCT_US |
| 4025243 | VANDF |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Dalbavancin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0480-3325 | INJECTION, POWDER, FOR SOLUTION | 500 mg | INTRAVENOUS | ANDA | 32 sections |
| DALVANCE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 57970-100 | INJECTION, POWDER, FOR SOLUTION | 500 mg | INTRAVENOUS | NDA | 32 sections |
| DALVANCE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 57970-100 | INJECTION, POWDER, FOR SOLUTION | 500 mg | INTRAVENOUS | NDA | 32 sections |
| DALBAVANCIN HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65219-120 | INJECTION, POWDER, FOR SOLUTION | 500 mg | INTRAVENOUS | ANDA | 31 sections |
| Dalbavancin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-034 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 500 mg | INTRAVENOUS | ANDA | 32 sections |
| Dalbavancin | Human Prescription Drug Label | 1 | 71839-144 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 500 mg | INTRAVENOUS | ANDA | 26 sections |
| Dalbavancin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 81298-2390 | INJECTION, POWDER, FOR SOLUTION | 500 mg | INTRAVENOUS | ANDA | 31 sections |